A novel second era FLT3 inhibitor.

Home / drugs / A novel second era FLT3 inhibitor.

A novel second era FLT3 inhibitor.

Additionally, non-clinical data will be presented evaluating the effect of AC220 monotherapy and in combination with chemotherapy. ‘AML is still a disease with a significant unmet medical need and brand-new therapies are urgently needed,’ said M. Scott Salka, Chief Executive Officer of Ambit Biosciences. ‘The Phase I scientific data we’ve noticed for AC220 in AML are extremely encouraging and supports the further advancement of this highly selective second-generation FLT3 inhibitor.’ Related StoriesPenn research forms basis for new treatment techniques for Sezary syndromePotential new drug target for severe myeloid leukemiaDr. Paul Liu named 2015 Distinguished Alumnus for contributions to leukemia researchData Highlights for AC220 consist of: ORAL PRESENTATIONS Abstract #636 AC220, a Powerful, Selective, Second Generation FLT3 Receptor Tyrosine Kinase Inhibitor, in a First-in-Human Phase 1 AML Study Provided by: Jorge Cortes, MD Session Name: Acute Myeloid Leukemia – Therapy, excluding Transplantation II Date: Monday, December 7, 2009, 5:45pm , Morial Convention Middle Space 343-345 POSTER PRESENTATIONS Abstract# 2053 AC220 – A FLT3 Inhibitor, Increases Survival in Two Genotypically Distinct FLT3-ITD Models of Acute Myeloid Leukemia and Provides Sustained Safety Following Chronic Administration Session Name: Acute Myeloid Leukemia – Therapy, excluding Transplantation II Sunday, December 6, 2009, 6:00 – 8:00pm, Hall E, Poster Board II-45 Abstract#: 2052 AC220, a Specific and Powerful FLT3 Inhibitor, Enhances the Cytotoxic Effects of Chemotherapeutic Brokers in Cell Lifestyle and in Mouse Tumor Xenograft Program Name: Acute Myeloid Leukemia – Therapy, excluding Transplantation II Sunday, December 6, 2009, 6:00 PM – 8:00 PM, Hall E, Poster Board II-44..There is no question that the partnership of Berg Pharma and Memorial Sloan – Kettering provides us nearer to finding a remedy for chemotherapy-induced alopecia. Mario Lacouture, MD, Associate Attending Skin doctor at Memorial Sloan-Kettering Cancers Principal and Middle Investigator of the trial, said, Hair thinning can be probably the most devastating unwanted effects of chemotherapy treatment therefore we have become excited to judge this fresh treatment in the expectations of possibly eliminating or significantly diminishing something that men and women consider to become a major stigma of several chemotherapeutic remedies. Related StoriesGenetic check that predicts recurrence of breasts cancer may impact usage of chemotherapyChemotherapy-induced nausea and vomiting most common distressing symptoms in most cancer patientsVA Medical center performs first effective heated chemotherapy bath on an individual with mesotheliomaThis Stage I trial has principal objectives of basic safety and pharmacokinetics and secondary goals designed to measure the capability of the topical medication to avoid or diminish hair thinning connected with chemotherapy treatments.